AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 89 filers reported holding AUDENTES THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $18,795,000 | -28.3% | 669,112 | -3.3% | 0.06% | -24.7% |
| Q2 2019 | $26,204,000 | +2.2% | 692,114 | +5.3% | 0.08% | 0.0% |
| Q1 2019 | $25,641,000 | +178.0% | 657,131 | +51.9% | 0.08% | +150.0% |
| Q4 2018 | $9,222,000 | -75.1% | 432,558 | -53.7% | 0.03% | -66.7% |
| Q3 2018 | $36,967,000 | +15.0% | 933,759 | +11.0% | 0.10% | +8.5% |
| Q2 2018 | $32,151,000 | +221.5% | 841,436 | +152.9% | 0.09% | +213.3% |
| Q1 2018 | $9,999,000 | +101.4% | 332,746 | +109.5% | 0.03% | +114.3% |
| Q4 2017 | $4,965,000 | – | 158,853 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |